Moringa Oleifera Tablets

Dosage: If not otherwise directed, adults may take two (2) tablets three times daily with meals, delivering an equivalent of ~3 g of Moringa oleifera leaf powder daily.
Adjust dosage according to individual clinical response and physician judgment.

Mechanism & key active components

• Rich in flavonoids (quercetin, kaempferol, myricetin), glucosinolates (notably glucomoringin → isothiocyanates), sterols (β-sitosterol), phenolic acids and carotenoids — contributing antioxidant, anti-inflammatory, hepatoprotective and cardio-metabolic effects.

Clinical evidence & dosing (high level)

• Multiple clinical and preclinical studies exist; overall evidence supports antioxidant, hepatoprotective and metabolic support. Clinical protocols vary; one published protocol used seed powder 3 g twice daily for 3 weeks in bronchial asthma patients. Many dietary interventions used 1–3 g leaf powder daily; dosing should be individualized.

Safety & toxicity

• Acute and subacute animal studies report LD50s and no major toxicity at moderate doses; oral administration of dried leaves up to 2000 mg/kg in animal studies was non-lethal; seed extracts show higher acute thresholds (4000–5000 mg/kg in rats). Human safety data indicate reasonable tolerability at typical supplement doses, but caution is needed regarding high doses and specific plant parts. Authors note a precautionary upper limit of ~70 g/day (cumulative intake) to avoid cumulative toxicity in some contexts — far above typical supplement doses, but relevant for high-dose botanical use.

Important clinical cautions / interactions

• Pregnancy & fertility: Some extracts (roots, high doses) show abortifacient or anti-fertility effects in animal models — contraindicate in pregnancy and advise caution in women trying to conceive.

• Glycemic effects: May lower blood glucose; monitor glucose when given with antidiabetic drugs (risk of additive hypoglycemia)

• Blood pressure / ACE inhibition: In silico and preclinical evidence suggests ACE-inhibitory potential (β-sitosterol and other compounds). Use caution when coadministered with antihypertensives; monitor blood pressure and electrolytes.

• Liver function: Some preclinical studies note changes in liver enzymes at higher doses; consider baseline/follow-up LFTs for long-term high-dose therapy.

Formulation & quality

• Use standardized extracts with assayable markers (e.g., total flavonoids, glucomoringin or an isothiocyanate marker) and third-party testing (heavy metals, microbial limits). The review lists validated analytical methods (HPLC, LC/MS) for quality control.

When to refer / avoid

• Avoid in pregnant patients. Use caution in severe hepatic impairment until more safety data is available. For patients on complex polypharmacy (anticoagulants, antidiabetics, antihypertensives), consider specialist consult prior to recommending high-dose extracts.